Grundlæggende statistik
| CIK | 930553 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ista Pharmaceuticals Inc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 18, 2012 |
FORM 15-12B OMB APPROVAL OMB Number: 3235-0167 Expires: December 31, 2014 Estimated average burden hours per response 1. |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 Post-Effective Amendment No. 3 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
AMENDED AND RESTATED ISTA PHARMACEUTICALS, INC. ARTICLE I Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ISTA PHARMACEUTICALS, INC. ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE. The registered office shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said company shall be the registered agent of this corporation. |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 S-8 POS 1 d363039ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-1 |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 Post-Effective Amendment No. 2 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 Post-Effective Amendment No. 2 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
ISTA / Ista Pharmaceuticals Inc / GAMCO INVESTORS, INC. ET AL Activist Investment SC 13D/A 1 ista03.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Ista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45031X204 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number o |
|
| June 6, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation or |
|
| June 6, 2012 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ISTA PHARMACEUTICALS, INC. ARTICLE ONE Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ISTA PHARMACEUTICALS, INC. ARTICLE ONE The name of the corporation is ISTA Pharmaceuticals, Inc. (hereinafter referred to as the “Corporation”). ARTICLE TWO The registered office of the Corporation is to be located at Corporation Service Company, 2711 Centerville Rd., Ste. 400, Wilmin |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 Post-Effective Amendment No. 2 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 Post-Effective Amendment No. 2 to Form S-3 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-173936 Registration Statement No. 333-155187 Registration Statement No. 333-154713 Registration Statement No. 333-144345 Registration Statement No. 333-144344 Registration Statement No. 333-135799 Registration Statement No. 333-114815 Registration Statement |
|
| June 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 6, 2012 Registration Statement No. 333-164358 Registration Statement No. 333-164357 Registration Statement No. 333-160348 Registration Statement No. 333-149621 Registration Statement No. 333-140577 Registration Statement No. 333-138204 Registration Statement No. 333-131793 Registration Statement |
|
| June 5, 2012 |
Press Release Exhibit 99.1 SOURCE: ISTA Pharmaceuticals Jun 05, 2012 ISTA Pharmaceuticals Stockholders Vote to Approve Acquisition by Bausch + Lomb IRVINE, CA - (Marketwire - June 5, 2012) - ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), announced that at the special meeting of ISTA stockholders held today, ISTA’s stockholders voted to approve the adoption of the previously announced Agreement and Pla |
|
| June 5, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) (C |
|
| June 5, 2012 |
ISTA / Ista Pharmaceuticals Inc / WATER ISLAND CAPITAL LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ISTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45031X201 - (CUSIP Number) 05/31/2012 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| May 29, 2012 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0R(#`@;V)J#3P\+TQI;F5AF4@-34O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R`A(,4X`$XPT@P1($)-A.`HG/DQF8&!EV@F09&-&)XRS@`$&`#6C@?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HU-"`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``(>4094P,@` MDN5H0!9C@6(&AAL,W`R7!E+U!A9V4^/@UE;F1O8FH-#4@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I<&4 |
|
| May 24, 2012 |
Proxy Statement Supplement Exhibit 99.1 50 Technology Drive Irvine, California 92618 SUPPLEMENT TO THE PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held on June 5, 2012 This supplement amends and supplements the definitive proxy statement, which we refer to as the Proxy Statement, initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 4, 2012 by ISTA P |
|
| May 24, 2012 |
- ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS Additional definitive proxy soliciting materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 24, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2012 ISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35396 33-0511729 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 24, 2012 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER Amendment No. 1 to Agreement and Plan of Merger Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment No. 1”) is entered into as of May 24, 2012, by and among Bausch & Lomb Incorporated, a New York corporation (the “Parent”), Inga Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of the Parent ( |
|
| May 7, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2012 |
ISTA / Ista Pharmaceuticals Inc / GAMCO INVESTORS, INC. ET AL Activist Investment SC 13D/A 1 ista02.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Ista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45031X204 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number o |
|
| May 4, 2012 |
Definitive Special Proxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2012 |
10-Q 1 d340348d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 MARCH 31, 2012 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSIT |
|
| May 4, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2012 Date of Report (Date of earliest event reported): May 3, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorp |
|
| May 4, 2012 |
FOURTH AMENDMENT TO BROMFENAC LICENSE AGREEMENT Fourth Amendment to Bromfenac License Agreement Exhibit 10.39 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. FOURTH AMENDMENT TO BROMFENAC LICENSE AGREEMENT This Fourth Amendment (the “Fourth Amendment”) is made |
|
| May 4, 2012 |
ISTA Pharmaceuticals Reports First Quarter 2012 Financial Results EX-99.1 2 d347003dex991.htm PRESS RELEASE Exhibit 99.1 ISTA Pharmaceuticals Reports First Quarter 2012 Financial Results IRVINE, CA — (Marketwire – May 3, 2012) — ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today reported on recent events and financial results for the quarter ended March 31, 2012. Recent Events • On March 26, 2012, ISTA entered into a definitive merger agreement with Bausch + Lomb |
|
| April 27, 2012 |
Annual Report - FORM 10-K AMENDMENT NO. 1 Form 10-K Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Fiscal Year Ended December 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 From the transition period from to Com |
|
| April 24, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| April 24, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) (Commissi |
|
| April 24, 2012 |
Press Release Exhibit 99.1 Bausch + Lomb and ISTA Pharmaceuticals Announce Early Termination of Hart-Scott-Rodino Waiting Period MADISON, NJ and IRVINE, CA, Apr 23, 2012 (MARKETWIRE via COMTEX) —Bausch + Lomb, the global eye health company, and ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced that they received early termination of the required waiting period under the Hart-Scott-Rodino |
|
| April 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| April 24, 2012 |
Press Release Exhibit 99.1 Bausch + Lomb and ISTA Pharmaceuticals Announce Early Termination of Hart-Scott-Rodino Waiting Period MADISON, NJ and IRVINE, CA, Apr 23, 2012 (MARKETWIRE via COMTEX) —Bausch + Lomb, the global eye health company, and ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced that they received early termination of the required waiting period under the Hart-Scott-Rodino |
|
| April 23, 2012 |
Preliminary Special Proxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 18, 2012 |
ISTA / Ista Pharmaceuticals Inc / GAMCO INVESTORS, INC. ET AL Activist Investment SC 13D/A 1 ista01.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Ista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45031X204 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number o |
|
| April 17, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| April 17, 2012 |
Text of E-Mail to Employees Exhibit 99.1 Hi, It has been a few weeks since we announced our planned combination with Bausch + Lomb, and I know that there are a lot of questions on your mind so wanted to update you on how things are progressing. ISTA and Bausch + Lomb continue to operate separately and independently, but there’s a fair amount of pre-combination planning that is required so we can h |
|
| April 17, 2012 |
Financial Statements and Exhibits, Other Events - AMENDMENT NO. 1 TO FORM 8-K Amendment No. 1 to Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State o |
|
| April 17, 2012 |
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC Text of E-mail to Employees Exhibit 99.1 Hi, It has been a few weeks since we announced our planned combination with Bausch + Lomb, and I know that there are a lot of questions on your mind so wanted to update you on how things are progressing. ISTA and Bausch + Lomb continue to operate separately and independently, but there’s a fair amount of pre-combination planning that is required so we can h |
|
| April 17, 2012 |
Amendment No. 1 to Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State o |
|
| April 17, 2012 |
Text of E-Mail to Employees Exhibit 99.1 Hi, It has been a few weeks since we announced our planned combination with Bausch + Lomb, and I know that there are a lot of questions on your mind so wanted to update you on how things are progressing. ISTA and Bausch + Lomb continue to operate separately and independently, but there’s a fair amount of pre-combination planning that is required so we can h |
|
| April 17, 2012 |
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC Text of E-mail to Employees Exhibit 99.1 Hi, It has been a few weeks since we announced our planned combination with Bausch + Lomb, and I know that there are a lot of questions on your mind so wanted to update you on how things are progressing. ISTA and Bausch + Lomb continue to operate separately and independently, but there’s a fair amount of pre-combination planning that is required so we can h |
|
| April 17, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| April 3, 2012 |
EX-10.1 2 d326713dex101.htm LOAN MODIFICATION AGREEMENT Exhibit 10.1 LOAN MODIFICATION AGREEMENT This Loan Modification Agreement (the “Agreement”) is entered into as of March 30, 2012, by and between ISTA PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”) and SILICON VALLEY BANK (“Bank”). 1. DESCRIPTION OF EXISTING INDEBTEDNESS: Among other indebtedness which may be owing by Borrower |
|
| April 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| April 2, 2012 |
EMPLOYEE Q&A #2 Acquisition of ISTA Pharmaceuticals Memorandum to Employees Exhibit 99.1 EMPLOYEE Q&A #2 Acquisition of ISTA Pharmaceuticals 1. Why is there not a variable for time of service worked in the severance plan? A. Our severance plan is based on competitive information obtained from our outside compensation consultant and determined to be at or above market for each level of payment. We also do not structure our rewards or recognition aro |
|
| April 2, 2012 |
Exhibit 99.1 This amendment is being filed to check the box indicating that the Reporting Person is no longer subject to Section 16. |
|
| April 2, 2012 |
ISTA / Ista Pharmaceuticals Inc / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Ista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45031X204 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices a |
|
| April 2, 2012 |
EMPLOYEE Q&A #2 Acquisition of ISTA Pharmaceuticals EX-99.1 2 d328665dex991.htm MEMORANDUM TO EMPLOYEES Exhibit 99.1 EMPLOYEE Q&A #2 Acquisition of ISTA Pharmaceuticals 1. Why is there not a variable for time of service worked in the severance plan? A. Our severance plan is based on competitive information obtained from our outside compensation consultant and determined to be at or above market for each level of payment. We also do not structure ou |
|
| April 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) (Commissio |
|
| April 2, 2012 |
ISTA / Ista Pharmaceuticals Inc / CREDIT SUISSE AG/ Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* ISTA Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45031X 20 4 (CUSIP Number) Ivy Dodes Credit Suisse AG Eleven Madison Avenue, New York, NY 10010 (212) 325-2000 (Name, Address and Telephone Number |
|
| April 2, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) ( |
|
| March 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| March 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| March 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 ISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35396 33-0511729 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 28, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 ISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35396 33-0511729 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 28, 2012 |
Agreement and Plan of Merger Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among BAUSCH & LOMB INCORPORATED, INGA ACQUISITION CORPORATION and ISTA PHARMACEUTICALS, INC. Dated as of March 26, 2012 TABLE OF CONTENTS ARTICLE I THE MERGER 1 1.1 The Merger 1 1.2 Effective Time of the Merger 1 1.3 Closing 2 1.4 Effects of the Merger 2 1.5 Directors and Officers of the Surviving Corporat |
|
| March 28, 2012 |
Agreement and Plan of Merger Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among BAUSCH & LOMB INCORPORATED, INGA ACQUISITION CORPORATION and ISTA PHARMACEUTICALS, INC. Dated as of March 26, 2012 TABLE OF CONTENTS ARTICLE I THE MERGER 1 1.1 The Merger 1 1.2 Effective Time of the Merger 1 1.3 Closing 2 1.4 Effects of the Merger 2 1.5 Directors and Officers of the Surviving Corporat |
|
| March 27, 2012 |
Press Release Exhibit 99.1 PRESS RELEASE BAUSCH + LOMB TO ACQUIRE ISTA PHARMACEUTICALS Combination Enhances Bausch + Lomb’s Growing Pharmaceutical Business; Creates Comprehensive Portfolio of Medicines; and Dramatically Expands D&R Pipeline MADISON, NJ and IRVINE, CA, Monday, March 26 – Bausch + Lomb, the global eye health company, and ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced tha |
|
| March 27, 2012 |
Amendment No. 1 to Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0511729 (State of incorporation or organization) (IRS Emplo |
|
| March 27, 2012 |
Press Release Exhibit 99.1 PRESS RELEASE BAUSCH + LOMB TO ACQUIRE ISTA PHARMACEUTICALS Combination Enhances Bausch + Lomb’s Growing Pharmaceutical Business; Creates Comprehensive Portfolio of Medicines; and Dramatically Expands D&R Pipeline MADISON, NJ and IRVINE, CA, Monday, March 26 – Bausch + Lomb, the global eye health company, and ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced tha |
|
| March 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| March 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| March 27, 2012 |
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC Text of E-Mail to Employees Exhibit 99.2 Good afternoon, As you know, for the last several months ISTA’s Board of Directors has been reviewing the company’s strategic options with the intent of delivering maximum value to the shareholders – which includes every one of us in this company. This morning, that process concluded with an announcement that Bausch + Lomb has entered into a definitive agre |
|
| March 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| March 27, 2012 |
AMENDMENT TO PREFERRED STOCK RIGHTS AGREEMENT Amendment to the Preferred Stock Rights Agreement Exhibit 4.2 AMENDMENT TO PREFERRED STOCK RIGHTS AGREEMENT THIS AMENDMENT TO PREFERRED STOCK RIGHTS AGREEMENT (this “Amendment”), dated as of March 26, 2012, between ISTA Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as Rights Agent (the “Rights Agent”), ame |
|
| March 27, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| March 27, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| March 27, 2012 |
IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC Text of E-Mail to Employees Exhibit 99.2 Good afternoon, As you know, for the last several months ISTA’s Board of Directors has been reviewing the company’s strategic options with the intent of delivering maximum value to the shareholders – which includes every one of us in this company. This morning, that process concluded with an announcement that Bausch + Lomb has entered into a definitive agre |
|
| March 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| March 27, 2012 |
EMPLOYEE Q&A Acquisition of ISTA Pharmaceuticals Memorandum to Employees Exhibit 99.3 EMPLOYEE Q&A Acquisition of ISTA Pharmaceuticals 1. Why are we selling the company? • After Valeant’s initial proposal to buy the company for $6.50 per share, ISTA’s board of directors ran a robust strategic review process, looking at all the options open to the company, to maximize shareholder value. • As one of the best known and most respected eye care brand |
|
| March 27, 2012 |
EMPLOYEE Q&A Acquisition of ISTA Pharmaceuticals Memorandum to Employees Exhibit 99.3 EMPLOYEE Q&A Acquisition of ISTA Pharmaceuticals 1. Why are we selling the company? • After Valeant’s initial proposal to buy the company for $6.50 per share, ISTA’s board of directors ran a robust strategic review process, looking at all the options open to the company, to maximize shareholder value. • As one of the best known and most respected eye care brand |
|
| March 26, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporation) |
|
| March 26, 2012 |
Press Release Exhibit 99.1 SOURCE: ISTA Pharmaceuticals Mar 26, 2012 09:24 ET ISTA Pharmaceuticals Announces Settlement on Royalty Dispute Settlement Results in Revised Royalty Agreement for BROMDAY(TM), XIBROM(TM) and PROLENSA(TM) IRVINE, CA-(Marketwire - March 26, 2012) - ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced it has settled all issues with Senju Pharmaceutical Co., Ltd. that |
|
| March 20, 2012 |
ISTA / Ista Pharmaceuticals Inc / CREDIT SUISSE AG/ Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ISTA Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45031X 20 4 (CUSIP Number) Ivy Dodes Credit Suisse AG Eleven Madison Avenue, New York, NY 10010 (212) 325-2000 (Name, Address and Telephone Number |
|
| March 16, 2012 |
Exhibit 99.1 (1) This amendment is being filed to correct the amount of securities beneficially owned following the transactions reported in Table I of the Form 4 filed on February 3, 2012. Other than as described in footnote 2, there are no other changes from the information originally reported. (2) This amendment is being filed to include two transactions omitted from Table I of the Form 4 filed |
|
| March 12, 2012 |
ISTA / Ista Pharmaceuticals Inc / WASATCH ADVISORS INC Passive Investment SC 13G/A 1 ista312.txt SCHEDULE 13G Amendment No. 1 Name of Issuer: Ista Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 45031X204 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 2,064, |
|
| February 27, 2012 |
ISTA PHARMACEUTICALS, INC. EXECUTIVE EMPLOYEE AGREEMENT Form of Executive Employment Agreement dated December 2, 2011 EXHIBIT 10.13 ISTA PHARMACEUTICALS, INC. EXECUTIVE EMPLOYEE AGREEMENT This Executive Employee Agreement (“Agreement”) is entered into as of , 2011 (the “Effective Date”), by and between (“Executive”) and ISTA Pharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company desires to continue to employ Executive to pr |
|
| February 27, 2012 |
ISTA PHARMACEUTICALS, INC. EXECUTIVE EMPLOYEE AGREEMENT Executive Employment Agreement dated November 30, 2011 EXHIBIT 10.12 ISTA PHARMACEUTICALS, INC. EXECUTIVE EMPLOYEE AGREEMENT This Executive Employee Agreement (“Agreement”) is entered into as of November 30, 2011 (the “Effective Date”), by and between Vince Anido (“Executive”) and ISTA Pharmaceuticals, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company desires to continue to employ |
|
| February 27, 2012 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2012 |
EXECUTIVE OFFICERS PARTY TO AN EXECUTIVE EMPLOYMENT AGREEMENT Schedule of Parties to Executive Employment Agreement EXHIBIT 10.13.1 EXECUTIVE OFFICERS PARTY TO AN EXECUTIVE EMPLOYMENT AGREEMENT Each of the individuals identified below is party to an executive employment agreement with ISTA Pharmaceuticals, Inc. in the form filed as Exhibit 10.13 to ISTA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011: Marvin J. Garrett Kathleen McGin |
|
| February 23, 2012 |
Press Release Exhibit 99.1 ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results – 2011 Net Revenues Increase to $160.3 Million – – On an Adjusted Cash Net Income Basis, ISTA Posts Second Year of Profitability – – Company Reaffirms 2012 Financial Guidance – IRVINE, Calif., February 23, 2012 (MARKETWIRE via COMTEX) — ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) announced tod |
|
| February 23, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 23, 2012 Date of Report (Date of earliest event reported): February 23, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of inc |
|
| February 17, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35396 33-0511729 (State or other jurisdiction of incorporatio |
|
| February 15, 2012 |
ISTA / Ista Pharmaceuticals Inc / Loeb Offshore Management LP - F12-02_1513D Activist Investment UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.1)* Ista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45031X204 (CUSIP Number) Alexander H. McMillan, Esq. Loeb Offshore Management LP 61 Broadway, New York, N.Y. 10006 (212) 483-7070 (Name, Address and Telephone Number of |
|
| February 14, 2012 |
ISTA / Ista Pharmaceuticals Inc / Flynn James E - AMENDMENT NO. 9 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 14, 2012 |
ISTA / Ista Pharmaceuticals Inc / WASATCH ADVISORS INC Passive Investment SCHEDULE 13G Amendment No. Name of Issuer: Ista Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 45031X204 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 2,143,929 Item 6: Shared Voting |
|
| February 9, 2012 |
ISTA / Ista Pharmaceuticals Inc / BlackRock Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ISTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45031X204 - (CUSIP Number) December 30, 2011 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 9, 2012 |
ISTA / Ista Pharmaceuticals Inc / CREDIT SUISSE AG/ Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ISTA Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45031X 20 4 (CUSIP Number) Ivy Dodes Credit Suisse AG Eleven Madison Avenue, New York, NY 10010 (212) 325-2000 (Name, Address and Telephone Number |
|
| February 1, 2012 |
UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Ista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45031X204 (CUSIP Number) Alexander H. McMillan, Esq. Loeb Offshore Management LP 61 Broadway, New York, N.Y. 10006 (212) 483-7070 (Name, Address and Telephone Number of P |
|
| January 17, 2012 |
Preferred Stock Rights Agreement Exhibit 4.1 ISTA PHARMACEUTICALS, INC. AND COMPUTERSHARE TRUST COMPANY, N.A. RIGHTS AGENT PREFERRED STOCK RIGHTS AGREEMENT DATED EFFECTIVE AS OF JANUARY 12, 2012 TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 10 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Counters |
|
| January 17, 2012 |
ISTA Pharmaceuticals Announces Adoption of a Replacement Stockholders Rights Plan Press Release Exhibit 99.1 ISTA Pharmaceuticals Announces Adoption of a Replacement Stockholders Rights Plan IRVINE, Calif., January 17, 2012 (MARKETWIRE via COMTEX) — ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced that its Board of Directors, in the best interests of the Company and shareholders, has adopted a stockholder rights plan (the “Rights Plan”) under which all stockholders of |
|
| January 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0511729 (State of incorporation or organization) (IRS Employer Identification No.) 50 Technology Drive, |
|
| January 17, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31255 33-0511729 (State or other jurisdiction of incorporation |
|
| January 17, 2012 |
- AMENDMENT NO. 3 TO THE FORM 8-A12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 3 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0511729 (State of incorporation or organization) (IRS Employer Identification No.) 50 T |
|
| January 17, 2012 |
THIRD AMENDMENT TO THE PREFERRED STOCK RIGHTS AGREEMENT Third Amendment to the Preferred Stock Rights Agreement Exhibit 4.2 THIRD AMENDMENT TO THE PREFERRED STOCK RIGHTS AGREEMENT THIS THIRD AMENDMENT TO THE PREFERRED STOCK RIGHTS AGREEMENT (this “Third Amendment”), dated as of January 12, 2012, by and between ISTA Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., as successor rights agent (the “Right |
|
| January 4, 2012 |
2012 Guidance and Pipeline Update Presentation - January 2012. 2012 Guidance and Pipeline Update January 4, 2012 Exhibit 99.2 ISTA PHARMACEUTICALS 2 • ISTA’s Track Record of Success – 2011: Solid Commercial and Pipeline Progress – Attractive portfolio of highly valuable assets • ISTA’s Financial Strategy and Outlook – 2012 Guidance – Delivering Value - Looking to 2015 and Beyond • ISTA Exploring S |
|
| January 4, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2012 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-31255 33-0511729 (State or other jurisdiction of incorporation) |
|
| January 4, 2012 |
Press release, dated January 4, 2012 EXHIBIT 99.1 ISTA Pharmaceuticals Announces Preliminary 2011 Revenue Results; Provides 2012 Financial Guidance and Updates Key Pipeline Milestones • Expects Profitability in 2011 for the Second Consecutive Year on an Adjusted Cash Net Income Basis • Unaudited 2011 Net Revenues Expected to be Greater than $160 Million • 2012 Net Revenues Expected to Grow to betw |
